1. SpO2 85% or less
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients age between 30 to 59 years old; 2. Patients with stage I hypertension (a blood pressure of at least 140/90 mm Hg and of unknown cause) diagnosed by medical specialists according to the JNC8 guidelines in spite of concurrent use of antihypertensive agents; 3. Patients had to be under optimal medication treatment for at least six months; 4. Patients had to be clinically stable (i.e. no crises or changes in medication) for at least three months.
Exclusion criteria
Exclusion criteria: 1. Patients have a serious respiratory disorder (e.g. asthma, COPD); 2. Patients have a history of cardiovascular diseases (e.g. acute myocardial infarction, and/or unstable angina), history of heart failure and stroke; 3. Patients presenting with history of neuromuscular and musculoskeletal diseases for more than one month; 4. Patients have an uncontrolled serious medical disease (e.g. CKD stage III); 5. Patients presenting with change of antihypertensive medication in the past 4 weeks before and during the experimental period; 6. Patients presenting with endocrine disorders (e.g. hyperthyroidism, hypothyroidism); 7. Woman in pregnancy and lactation; 8. Patients had to be continuous exposure for more than one week to altitudes above 1,000 m during the three months preceding inclusion in the study; 9. Patients who participate in the weight loss program or use of weight loss drugs; 10. People with altitude sickness (e.g. bad headache, nausea, dizziness and feel exhausted) during the training sessions and cannot continue the experimental period; 11. Patients who cannot participate in the intermittent hypoxic exposure or training continuously; 12. People with psychology signs and symptoms (e.g. anxiety, depression).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure, nitric oxide levels, hypoxia-inducible factor 1 aplha 1 day before intervention (PRE), 1 day and 4 weeks after intervention (POST1 and 2) Blood Pressure Monitor, Total Nitric Oxide Assay Kit, Human HIF1 alpha ELISA kit | — |
Secondary
| Measure | Time frame |
|---|---|
| heart rate variability, aerobic performance, body composition, lipid profiles 1 day before intervention (PRE), 1 day and 4 weeks after intervention (POST1 and 2) HRV analyzer and a Tanita BC-418 Analyzer | — |
Countries
Thailand
Contacts
Department of Physiology Faculty of Medicine Khon Kaen University Muang, Khon Kaen Thailand 40002